Evidence map›Paper›PMID 38966556›Full record

ReviewFrontiers in pharmacology2024

Blended e-learning and certification for medicines development professionals: results of a 7-year collaboration between King's College, London and the GMDP Academy, New York.

Honorio Silva, Peter Stonier, Pravin Chopra, Jacob Coots, Domenico Criscuolo, Soneil Guptha, Stuart Jones, Sandor Kerpel-Fronius, Gustavo Kesselring, Xavier Luria and 7 more

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Honorio Silva *GMDP Academy, The Academy of Global Medicines Development Professionals, New York, NY, United States.
Peter StonierCenter for Pharmaceutical Medicine Research, King's College London, London, United Kingdom.
Pravin ChopraGMDP Academy, The Academy of Global Medicines Development Professionals, New York, NY, United States.
Jacob CootsGMDP Academy, The Academy of Global Medicines Development Professionals, New York, NY, United States.
Domenico CriscuoloGenovax Pharma, Milan, Italy.
Soneil GupthaGMDP Academy, The Academy of Global Medicines Development Professionals, New York, NY, United States.
Stuart JonesCenter for Pharmaceutical Medicine Research, King's College London, London, United Kingdom.
Sandor Kerpel-FroniusSemmelweis University, Budapest, Hungary.
Gustavo KesselringCenter for Pharmaceutical Medicine Research, King's College London, London, United Kingdom.
Xavier LuriaCenter for Pharmaceutical Medicine Research, King's College London, London, United Kingdom.
David MorganCenter for Pharmaceutical Medicine Research, King's College London, London, United Kingdom.
Eddie PowerCenter for Pharmaceutical Medicine Research, King's College London, London, United Kingdom.
Sam SalekPharmaTrain Federation, Brussels, Belgium.
Gustavo SilvaGMDP Academy, The Academy of Global Medicines Development Professionals, New York, NY, United States.
Tamas SutoMerck Group, Eysins, Switzerland.
Kamlesh ThakkerGMDP Academy, The Academy of Global Medicines Development Professionals, New York, NY, United States.
Pol VandenbrouckeCenter for Pharmaceutical Medicine Research, King's College London, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The field of Medicines Development faces a continuous need for educational evolution to match the interdisciplinary and global nature of the pharmaceutical industry. This paper discusses the outcomes of a 7-year collaboration between King's College London and the Global Medicines Development Professionals (GMDP) Academy, which aimed to address this need through a blended e-learning program. Methods: The collaboration developed a comprehensive curriculum based on the PharmaTrain syllabus, delivered through a combination of asynchronous and synchronous e-learning methods. The program targeted a diverse range of professionals serving in areas related to Medical Affairs. Results: Over seven annual cohorts, 682 participants from eighty-six countries were enrolled in the program. The program's effectiveness was assessed using Kirkpatrick's model, showing elevated levels of satisfaction (over 4.0 on a five-point scale), suggesting significant gains in competence at the cognitive level and leveraged performance. Notably, 70% of responding alumni reported significant improvement in their functions, corroborated by 30% of their supervisors. The further long-term impact of the program on their respective organization has not been established. Discussion: The GMDP Academy's program has significantly contributed to life-long learning in Medicines Development, addressing educational gaps and fostering interdisciplinary collaboration. Its success highlights the importance of continuous education in keeping pace with the industry's evolving demands and underscores the potential of blended learning in achieving educational objectives in pharmaceutical medicine.

Indexed as

certificationcontinuing professional developmente-learningKing’slife-long learningmedicines developmentpharmaceutical medicine

Identifiers

PMID38966556
PMCPMC11223568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.